Lactobacillus reuteri E9 regulates sleep disorders through its metabolite GABA by modulating inhibitory neurotransmitters and sleep-related receptor expression.
Lactobacillus reuteri E9 significantly upregulated inhibitory neurotransmitters including GABA, taurine, glycine, and serine (p < 0.05) in a PTZ-induced zebrafish model of sleep disorder. It reduced seizures and hyperactivity, and upregulated GABA receptor genes and melatonin receptor (Mtnr1aa) genes in zebrafish neural tissue.
Evidence Score
Study Evidence
Study 1. Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA.
observationalJiang Y, Guo L, He H, Chen H, Chen T, Liu Y, Zhao W ยท Frontiers in bioscience (Landmark edition) (2025)
Result:
Mechanism Graph
Limitations
- โ Animal model (zebrafish) may not fully translate to human sleep disorders
- โ Abstract does not report effect sizes or confidence intervals for key outcomes
Frequently Asked Questions
What is Lactobacillus reuteri E9?โผ
It is a non-toxic, drug-resistant probiotic strain isolated and characterized for its potential to regulate sleep disorders via the microbiota-gut-brain axis.
How does Lactobacillus reuteri E9 affect sleep?โผ
It upregulates inhibitory neurotransmitters like GABA, taurine, glycine, and serine, and increases expression of GABA and melatonin receptor genes, leading to sedative effects in a zebrafish model.
What model was used to test Lactobacillus reuteri E9?โผ
A pentylenetetrazol (PTZ)-induced zebrafish model of sleep disorder was used to evaluate its effects.
Is Lactobacillus reuteri E9 safe for humans?โผ
The abstract states it is non-toxic and drug-resistant, but human studies are needed to confirm safety and efficacy.
Products
Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.
References
- 1.Jiang Y, Guo L, He H, Chen H, Chen T, Liu Y, Zhao W. "Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA.." Frontiers in bioscience (Landmark edition), 2025. PMID: 40613302 DOI: 10.31083/FBL39587